EA201892625A1 - КОМБИНИРОВАННАЯ ТЕРАПИЯ С ПРИМЕНЕНИЕМ ИНГИБИТОРА АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ (ACC) ДЛЯ ЛЕЧЕНИЯ НЕАЛКОГОЛЬНОЙ ЖИРОВОЙ БОЛЕЗНИ ПЕЧЕНИ - Google Patents
КОМБИНИРОВАННАЯ ТЕРАПИЯ С ПРИМЕНЕНИЕМ ИНГИБИТОРА АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ (ACC) ДЛЯ ЛЕЧЕНИЯ НЕАЛКОГОЛЬНОЙ ЖИРОВОЙ БОЛЕЗНИ ПЕЧЕНИInfo
- Publication number
- EA201892625A1 EA201892625A1 EA201892625A EA201892625A EA201892625A1 EA 201892625 A1 EA201892625 A1 EA 201892625A1 EA 201892625 A EA201892625 A EA 201892625A EA 201892625 A EA201892625 A EA 201892625A EA 201892625 A1 EA201892625 A1 EA 201892625A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- disease
- acc
- alcoholic
- carboxylase
- coa
- Prior art date
Links
- 102000000452 Acetyl-CoA carboxylase Human genes 0.000 title 2
- 108010016219 Acetyl-CoA carboxylase Proteins 0.000 title 2
- 108010018763 Biotin carboxylase Proteins 0.000 title 2
- 238000002648 combination therapy Methods 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 208000019423 liver disease Diseases 0.000 title 1
- 229940121373 acetyl-coa carboxylase inhibitor Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 1
- 230000000087 stabilizing effect Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562101726P | 2015-01-09 | 2015-01-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201892625A1 true EA201892625A1 (ru) | 2019-07-31 |
Family
ID=56356482
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201892625A EA201892625A1 (ru) | 2015-01-09 | 2016-01-08 | КОМБИНИРОВАННАЯ ТЕРАПИЯ С ПРИМЕНЕНИЕМ ИНГИБИТОРА АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ (ACC) ДЛЯ ЛЕЧЕНИЯ НЕАЛКОГОЛЬНОЙ ЖИРОВОЙ БОЛЕЗНИ ПЕЧЕНИ |
| EA201791258A EA201791258A1 (ru) | 2015-01-09 | 2016-01-08 | Комбинированная терапия с применением ингибитора ацетил-коа-карбоксилазы (acc) для лечения неалкогольной жировой болезни печени |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201791258A EA201791258A1 (ru) | 2015-01-09 | 2016-01-08 | Комбинированная терапия с применением ингибитора ацетил-коа-карбоксилазы (acc) для лечения неалкогольной жировой болезни печени |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20180021341A1 (enExample) |
| EP (2) | EP3597271A1 (enExample) |
| JP (2) | JP2018501276A (enExample) |
| KR (1) | KR20170102299A (enExample) |
| CN (1) | CN107106873A (enExample) |
| AU (1) | AU2016205138A1 (enExample) |
| BR (1) | BR112017014341A2 (enExample) |
| CA (1) | CA2972919A1 (enExample) |
| EA (2) | EA201892625A1 (enExample) |
| HK (2) | HK1243369A1 (enExample) |
| MX (1) | MX2017008844A (enExample) |
| SG (1) | SG11201705361PA (enExample) |
| WO (1) | WO2016112305A1 (enExample) |
Families Citing this family (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT1993360T (lt) | 2005-12-28 | 2017-06-12 | Vertex Pharmaceuticals Incorporated | N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma |
| TWI625121B (zh) | 2009-07-13 | 2018-06-01 | 基利科學股份有限公司 | 調節細胞凋亡信號之激酶的抑制劑 |
| WO2011140441A2 (en) | 2010-05-06 | 2011-11-10 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into intestinal tissues through directed differentiation |
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| US11571431B2 (en) | 2013-12-04 | 2023-02-07 | Galmed Research And Development Ltd | Aramchol salts |
| ES2860423T3 (es) | 2014-05-28 | 2021-10-05 | Childrens Hospital Med Ct | Métodos y sistemas para convertir células precursoras en tejidos gástricos mediante diferenciación dirigida |
| CA2963704A1 (en) | 2014-10-17 | 2016-04-21 | Children's Hospital Medical Center | In vivo model of human small intestine using pluripotent stem cells and methods of making and using same |
| ES2734713T3 (es) | 2015-07-06 | 2019-12-11 | Gilead Sciences Inc | Moduladores Cot y métodos de utilización de los mismos |
| EP3380478B1 (en) | 2015-11-25 | 2020-12-23 | Gilead Apollo, LLC | Ester acc inhibitors and uses thereof |
| US20170166582A1 (en) * | 2015-11-25 | 2017-06-15 | Gilead Apollo, Llc | Pyrazole acc inhibitors and uses thereof |
| IL243707A0 (en) | 2016-01-20 | 2016-05-01 | Galmed Res And Dev Ltd | Treatment to regulate the microbiota in the intestine |
| CA3155220C (en) | 2016-03-02 | 2024-01-16 | Gilead Apollo, Llc | Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof |
| CN109415685B (zh) | 2016-05-05 | 2023-07-04 | 儿童医院医疗中心 | 用于体外制造胃底组织的方法和与其相关的组合物 |
| NZ748641A (en) | 2016-06-13 | 2020-04-24 | Gilead Sciences Inc | Fxr (nr1h4) modulating compounds |
| CA2968836C (en) | 2016-06-13 | 2025-09-02 | Gilead Sciences, Inc. | FXR MODULATING COMPOUNDS (NR1H4) |
| SG10202104575WA (en) | 2016-11-04 | 2021-06-29 | Childrens Hospital Med Ct | Liver organoid compositions and methods of making and using same |
| JP2019537607A (ja) * | 2016-11-10 | 2019-12-26 | ガルメド リサーチ アンド ディベロップメント リミテッド | 非アルコール性脂肪性肝疾患の患者における線維化の抑制 |
| US11197870B2 (en) | 2016-11-10 | 2021-12-14 | Galmed Research And Development Ltd | Treatment for hepatic fibrosis |
| CA3152584C (en) * | 2016-11-10 | 2024-02-13 | Galmed Research And Development Ltd. | Treatment for fibrosis |
| CA3045145A1 (en) | 2016-12-05 | 2018-06-14 | Children's Hospital Medical Center | Colonic organoids and methods of making and using same |
| US11040027B2 (en) | 2017-01-17 | 2021-06-22 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| AU2018209006B2 (en) * | 2017-01-22 | 2021-04-22 | Sunshine Lake Pharma Co., Ltd. | Thienopyrimidine derivative and use thereof in medicine |
| CN110431144B (zh) * | 2017-03-24 | 2022-08-05 | 浙江海正药业股份有限公司 | 氰基取代的杂芳基并嘧啶酮类衍生物及其制备方法和用途 |
| US20180311244A1 (en) * | 2017-03-28 | 2018-11-01 | Gilead Sciences, Inc. | Methods of treating liver disease |
| ES2982801T3 (es) * | 2017-03-28 | 2024-10-17 | Gilead Sciences Inc | Combinaciones terapéuticas para el tratamiento de las enfermedades hepáticas |
| EP3609496A1 (en) * | 2017-04-12 | 2020-02-19 | Gilead Sciences, Inc. | Methods of treating liver disease |
| US12281334B2 (en) | 2017-04-14 | 2025-04-22 | Children's Hospital Medical Center | Multi donor stem cell compositions and methods of making same |
| CA3058542A1 (en) * | 2017-04-18 | 2018-10-25 | Genfit | Combination comprising a ppar agonist such as elafibranor and an acetyl-coa carboxylase (acc) inhibitor |
| EP3609523B1 (en) * | 2017-04-24 | 2022-03-02 | Tsinghua University | Use of autoinducer-related pathway in inducing apoptosis and anti-infective therapy |
| US20200129511A1 (en) * | 2017-06-19 | 2020-04-30 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of nafld and nash |
| WO2019015583A1 (en) * | 2017-07-17 | 2019-01-24 | Nanjing Ruijie Pharmatech Co., Ltd. | NOVEL COMPOUNDS AND THEIR USES AS ACC INHIBITORS |
| EP3660023B1 (en) * | 2017-07-26 | 2023-03-08 | Nanjing Sanhome Pharmaceutical Co., Ltd. | Thienopyrimidinedione compounds as acc inhibitors and use thereof |
| CN109316601B (zh) * | 2017-07-31 | 2021-11-09 | 武汉朗来科技发展有限公司 | 药物组合物及其用途 |
| US11542256B2 (en) | 2017-09-03 | 2023-01-03 | Angion Biomedica Corp. | Vinylheterocycles as Rho-associated coiled-coil kinase (ROCK) inhibitors |
| US11033601B2 (en) * | 2017-09-14 | 2021-06-15 | The Regents Of The University Of Colorado, A Body Corporate | Selective inhibition of V1b for treating fatty liver |
| CN111182904A (zh) * | 2017-10-06 | 2020-05-19 | 吉利德科学公司 | 包含acc抑制剂的组合治疗 |
| WO2019074793A1 (en) | 2017-10-10 | 2019-04-18 | Children's Hospital Medical Center | OESOPHAGIAN TISSUE COMPOSITIONS AND / OR ORGANOIDS AND METHODS OF MAKING SAME |
| US11419918B2 (en) * | 2017-11-06 | 2022-08-23 | Shenzhen Turier Biotech Co., Ltd. | Treatment of biliary cirrhosis based on oxyntomodulin analogue GLP-1R/GCGR dual-target agonist peptide |
| CN107693514A (zh) * | 2017-12-04 | 2018-02-16 | 威海贯标信息科技有限公司 | 一种鲁格列净组合物 |
| US12379372B2 (en) | 2017-12-21 | 2025-08-05 | Children's Hospital Medical Center | Digitalized human organoids and methods of using same |
| AU2019216264B2 (en) | 2018-01-31 | 2023-08-31 | Heparegenix Gmbh | Protein kinase MKK4 inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| US20210113561A1 (en) * | 2018-04-17 | 2021-04-22 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| KR20210002573A (ko) * | 2018-04-24 | 2021-01-08 | 주식회사 피에이치파마 | 간 질환에 호중구 엘라스타제 저해제의 사용 |
| WO2019243315A1 (en) | 2018-06-21 | 2019-12-26 | Heparegenix Gmbh | Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| SG11202012732UA (en) | 2018-07-16 | 2021-02-25 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| CA3106634A1 (en) | 2018-07-26 | 2020-01-30 | Children's Hospital Medical Center | Hepato-biliary-pancreatic tissues and methods of making same |
| JP2022514731A (ja) * | 2018-08-14 | 2022-02-15 | アヴォリント | 原発性硬化性胆管炎の処置方法 |
| JP7161605B2 (ja) | 2018-08-31 | 2022-10-26 | ファイザー・インク | Ｎａｓｈ／ｎａｆｌｄおよび関連疾患の治療のための組合せ |
| CA3111025C (en) * | 2018-09-06 | 2023-10-31 | Galmed Research And Development Ltd | Combination therapy for the treatment of liver disease |
| CN112823012A (zh) | 2018-09-12 | 2021-05-18 | 儿童医院医学中心 | 用于产生造血干细胞及其衍生物的类器官组合物 |
| CN110950884B (zh) * | 2018-09-27 | 2024-03-26 | 上海翰森生物医药科技有限公司 | 含二并环类衍生物抑制剂、其制备方法和应用 |
| AU2019385438A1 (en) * | 2018-11-20 | 2021-05-27 | The National Institutes of Pharmaceutical R&D Co., Ltd. | Spiro compound and medical uses thereof |
| KR102692309B1 (ko) | 2019-01-15 | 2024-08-07 | 길리애드 사이언시즈, 인코포레이티드 | Fxr (nr1h4) 조정 화합물 |
| WO2020160371A1 (en) | 2019-02-01 | 2020-08-06 | The University Of Hong Kong | Innervated organoid compositions and methods of making same |
| WO2020172075A1 (en) | 2019-02-19 | 2020-08-27 | Gilead Sciences, Inc. | Solid forms of fxr agonists |
| WO2020208205A1 (en) * | 2019-04-10 | 2020-10-15 | Genfit | Combination therapy comprising compounds of formula (i) and glp-1 receptor agonists |
| WO2020227549A1 (en) | 2019-05-08 | 2020-11-12 | Aligos Therapeutics, Inc. | MODULATORS OF THR-β AND METHODS OF USE THEREOF |
| US12534709B2 (en) | 2019-05-31 | 2026-01-27 | Children's Hospital Medical Center | Shaped organoid compositions and methods of making same |
| CA3141807A1 (en) | 2019-05-31 | 2020-12-03 | Children's Hospital Medical Center | Methods of generating and expanding hematopoietic stem cells |
| TWI915558B (zh) | 2019-06-14 | 2026-02-21 | 美商基利科學股份有限公司 | Cot 調節劑及其使用方法 |
| CN113924303B (zh) * | 2019-07-02 | 2023-10-20 | 广东东阳光药业股份有限公司 | 具有立体构型的噻吩并嘧啶衍生物及其在药物中的应用 |
| JP7629442B2 (ja) | 2019-07-29 | 2025-02-13 | ヘパリジェニックス ゲーエムベーハー | 肝臓再生を促進または肝細胞死を縮減もしくは防止するためのヘテロアリール置換ピラゾロ－ピリジンタンパク質キナーゼ阻害剤 |
| AR119594A1 (es) | 2019-08-09 | 2021-12-29 | Gilead Sciences Inc | Derivados de tienopirimidina como inhibidores acc y usos de los mismos |
| CN110628810B (zh) * | 2019-08-13 | 2022-06-28 | 浙江大学 | 一种提高植物光合效率的方法 |
| CN114340632B (zh) * | 2019-08-30 | 2024-09-17 | 赛特瑞恩股份有限公司 | 用于治疗或预防非酒精性脂肪性肝炎（nash）的药物组合物 |
| US20230105984A1 (en) | 2019-12-23 | 2023-04-06 | Svetlana Marukian | Compositions and methods for the treatment of liver diseases and disorders |
| CA3164361A1 (en) | 2020-01-15 | 2021-07-22 | Heparegenix Gmbh | 3-benzoyl-1h-pyrrolo[2,3-b]pyridine derivatives as mkk4 inhibitors for treating liver diseases |
| JP2022058085A (ja) | 2020-02-24 | 2022-04-11 | ファイザー・インク | ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ |
| JP2021134211A (ja) | 2020-02-24 | 2021-09-13 | ファイザー・インク | Ｎａｆｌｄ／ｎａｓｈおよび関連疾患の処置のための組合せ |
| IL296100A (en) * | 2020-03-11 | 2022-11-01 | Dong A St Co Ltd | A medicinal preparation for the prevention or treatment of non-alcoholic steatohepatitis |
| CA3175541A1 (en) | 2020-03-30 | 2021-10-07 | Gilead Sciences, Inc. | Solid forms of (s)-6-(((1-(bicyclo[1.1.1]pentan-1-yl)-1h-1,2,3-triazol-4-yl)2-methyl-1-oxo-1,2- dihydroisoquinolin-5-yl)methyl)))amino)8-chloro-(neopentylamino)quinoline-3-carb onitrile a cot inhibitor compound |
| EP4126862B1 (en) | 2020-04-02 | 2025-05-21 | Gilead Sciences, Inc. | Process for preparing a cot inhibitor compound |
| CN111407892A (zh) * | 2020-04-08 | 2020-07-14 | 中国药科大学 | Acsl4及其在nash中的应用 |
| US11478533B2 (en) | 2020-04-27 | 2022-10-25 | Novo Nordisk A/S | Semaglutide for use in medicine |
| KR20230013126A (ko) | 2020-05-21 | 2023-01-26 | 시오노기 앤드 컴파니, 리미티드 | 지방성 간질환의 치료용 의약 |
| EP4000616A1 (en) * | 2020-11-17 | 2022-05-25 | Inventiva | Combination therapy for the treatment of a liver disease |
| EP4304711A1 (en) | 2021-03-11 | 2024-01-17 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| ES3061522T3 (en) | 2021-03-29 | 2026-04-06 | Gilead Sciences Inc | Khk inhibitors |
| TW202345826A (zh) | 2021-06-04 | 2023-12-01 | 美商基利科學股份有限公司 | 治療nash之方法 |
| TW202311256A (zh) | 2021-06-18 | 2023-03-16 | 美商基利科學股份有限公司 | 用於治療ｆｘｒ誘發之搔癢之ｉｌ－３１調節劑 |
| WO2023034381A1 (en) * | 2021-08-31 | 2023-03-09 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Quantitative systems pharmacology methods for identifying therapeutics for disease states |
| WO2023047203A1 (en) * | 2021-09-25 | 2023-03-30 | Torrent Pharmaceuticals Ltd | Combination of omzotirome and antidiabetic agent, antihypertensive agent or anti-dyslipidemic agent |
| JPWO2023090411A1 (enExample) | 2021-11-19 | 2023-05-25 | ||
| EP4731212A1 (en) * | 2023-06-20 | 2026-04-29 | Sagimet Biosciences Inc. | Combination therapies of fasn inhibitors with thyroid hormone receptor agonists |
| KR20250155468A (ko) * | 2024-04-22 | 2025-10-30 | 연세대학교 원주산학협력단 | CCR2 억제제와 TGF-β 수용체 억제제의 병용투여를 통한 대사이상관련 지방간염 치료 방법 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009155611A1 (en) * | 2008-06-20 | 2009-12-23 | Kinemed, Inc. | Compositions for the treatment of fibrotic diseases or conditions |
| US20100113473A1 (en) * | 2008-10-30 | 2010-05-06 | Player Mark R | Aryl amide compound as an acetyl coenzyme a carboxylase inhibitor |
| WO2012090219A2 (en) * | 2010-12-31 | 2012-07-05 | Jubilant Biosys Ltd. | Thiazole compounds useful as acetyl-coa carboxylase (acc) inhibitors |
| MX370976B (es) * | 2011-11-11 | 2020-01-10 | Gilead Apollo Llc | Inhibidores de acetil coa carboxilasa (acc) y usos de los mismos. |
| AU2014262636A1 (en) * | 2013-05-10 | 2015-11-26 | Gilead Apollo, Llc | ACC inhibitors and uses thereof |
| EA201591962A1 (ru) | 2013-05-10 | 2016-06-30 | Нимбус Аполло, Инк. | Ингибиторы акк и их применение |
| EP2994128B1 (en) | 2013-05-10 | 2019-01-30 | Gilead Apollo, LLC | Acc inhibitors and uses thereof |
| AU2014262638A1 (en) | 2013-05-10 | 2015-11-26 | Gilead Apollo, Llc | ACC inhibitors and uses thereof |
-
2016
- 2016-01-08 MX MX2017008844A patent/MX2017008844A/es unknown
- 2016-01-08 WO PCT/US2016/012673 patent/WO2016112305A1/en not_active Ceased
- 2016-01-08 EA EA201892625A patent/EA201892625A1/ru unknown
- 2016-01-08 HK HK18102859.6A patent/HK1243369A1/zh unknown
- 2016-01-08 BR BR112017014341-0A patent/BR112017014341A2/pt not_active Application Discontinuation
- 2016-01-08 SG SG11201705361PA patent/SG11201705361PA/en unknown
- 2016-01-08 CA CA2972919A patent/CA2972919A1/en not_active Abandoned
- 2016-01-08 EA EA201791258A patent/EA201791258A1/ru unknown
- 2016-01-08 CN CN201680004801.2A patent/CN107106873A/zh active Pending
- 2016-01-08 US US15/541,008 patent/US20180021341A1/en not_active Abandoned
- 2016-01-08 EP EP19176040.4A patent/EP3597271A1/en not_active Withdrawn
- 2016-01-08 AU AU2016205138A patent/AU2016205138A1/en not_active Abandoned
- 2016-01-08 KR KR1020177021086A patent/KR20170102299A/ko not_active Withdrawn
- 2016-01-08 HK HK18105783.0A patent/HK1246232A1/zh unknown
- 2016-01-08 JP JP2017535411A patent/JP2018501276A/ja not_active Withdrawn
- 2016-01-08 EP EP16735485.1A patent/EP3242722A4/en not_active Withdrawn
-
2019
- 2019-05-13 US US16/410,894 patent/US20190381045A1/en not_active Abandoned
-
2020
- 2020-04-15 JP JP2020072689A patent/JP2020109130A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112017014341A2 (pt) | 2018-03-27 |
| HK1243369A1 (zh) | 2018-07-13 |
| EP3242722A4 (en) | 2018-07-11 |
| WO2016112305A1 (en) | 2016-07-14 |
| AU2016205138A1 (en) | 2017-07-13 |
| CA2972919A1 (en) | 2016-07-14 |
| HK1246232A1 (zh) | 2018-09-07 |
| EP3242722A1 (en) | 2017-11-15 |
| JP2020109130A (ja) | 2020-07-16 |
| US20180021341A1 (en) | 2018-01-25 |
| MX2017008844A (es) | 2018-03-14 |
| SG11201705361PA (en) | 2017-08-30 |
| EA201791258A1 (ru) | 2017-12-29 |
| JP2018501276A (ja) | 2018-01-18 |
| EP3597271A1 (en) | 2020-01-22 |
| KR20170102299A (ko) | 2017-09-08 |
| CN107106873A (zh) | 2017-08-29 |
| US20190381045A1 (en) | 2019-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201791258A1 (ru) | Комбинированная терапия с применением ингибитора ацетил-коа-карбоксилазы (acc) для лечения неалкогольной жировой болезни печени | |
| JOP20200142A1 (ar) | بنيات rnai لتثبيط التعبير عن pnpla3 وطرق استخدامها | |
| CL2019002368A1 (es) | Composiciones y métodos para el tratamiento de cáncer. | |
| CO2018012894A2 (es) | Derivados de pirazol como inhibidores de calicreína plasmática | |
| EA201591509A1 (ru) | Ингибиторы cdc7 | |
| BR112018001853A2 (pt) | métodos para tratamento de um distúrbio e para melhoria do tratamento de um distúrbio | |
| EA201790998A1 (ru) | Иммуннорегуляторные агенты | |
| MX2017010773A (es) | Inhibidores de muerte programada 1 (pd-19)/ligando de muerte progamada 1 (pd-l1) para el tratamiento de cancer. | |
| MX2018005315A (es) | Composiciones y metodos para el tratamiento del cancer. | |
| MX378969B (es) | Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres. | |
| UY36357A (es) | Composiciones y métodos para la inhibición de la expresión génica de hao1 (hidroxiácido oxidasa 1 (glicolato oxidasa)) | |
| MX2018008105A (es) | Compuestos inhibidores de metaloenzima. | |
| EA201891340A1 (ru) | Лечение рака с использованием 2-дезокси-2-фтор-l-фукозы в комбинации с ингибитором контрольных точек | |
| MX2018005233A (es) | Combinacion de inhibidor de bcl-2 e inhibidor de mek para el tratamiento de cancer. | |
| SG10201808940WA (en) | Nox inhibitor and nfкb inhibitor containing methoxyflavone | |
| MX2019007892A (es) | Compuestos inhibidores de metaloenzimas. | |
| MX2018012493A (es) | Métodos para controlar y tratar el cáncer. | |
| EA201792604A1 (ru) | Ингибиторы аутотаксина и их применения | |
| MX385762B (es) | Métodos para el control transcripcional objetivo en regiones del super mejorador. | |
| MX382996B (es) | Inhibidores de pcna | |
| MX386146B (es) | Métodos para tratar esclerosis múltiple usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton. | |
| MX382904B (es) | Combinaciones de fármacos para tratar mieloma múltiple. | |
| UY37017A (es) | Inhibidores aza-bencimidazol de pad4 | |
| PH12017501879A1 (en) | Methods for treating cancer | |
| EA201990567A1 (ru) | Комбинированная терапия с ингибиторами глутаминазы |